Revance Therapeutics shares are trading lower after the company said it commenced a plan to exit the OPUL payments business and expects to record a restructuring charge of up to $7 million.
Portfolio Pulse from Benzinga Newsdesk
Revance Therapeutics has announced plans to exit the OPUL payments business, expecting to record a restructuring charge of up to $7 million. This has led to a decrease in the company's share price.
September 19, 2023 | 3:33 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Revance Therapeutics' decision to exit the OPUL payments business and the expected restructuring charge of up to $7 million has negatively impacted its share price.
Revance Therapeutics' decision to exit the OPUL payments business and the associated restructuring charge is a significant event for the company. This decision has led to uncertainty among investors, resulting in a decrease in the company's share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100